264 related articles for article (PubMed ID: 17085670)
21. Heat shock protein 90 inhibitor regulates necroptotic cell death via down-regulation of receptor interacting proteins.
Park SY; Shim JH; Chae JI; Cho YS
Pharmazie; 2015 Mar; 70(3):193-8. PubMed ID: 25980180
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
23. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
24. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
25. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Münster PN; Basso A; Solit D; Norton L; Rosen N
Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
[TBL] [Abstract][Full Text] [Related]
26. Heat shock protein 90 inhibitor enhances apoptosis by inhibiting the AKT pathway in thermal-stimulated SK-MEL-2 human melanoma cell line.
Shin MK; Jeong KH; Choi H; Ahn HJ; Lee MH
J Dermatol Sci; 2018 Jun; 90(3):357-360. PubMed ID: 29433909
[TBL] [Abstract][Full Text] [Related]
27. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
Kim HJ; Gong MK; Yoon CY; Kang J; Yun M; Cho NH; Rha SY; Choi YD
Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells.
Zhang J; Li H; Huang Z; He Y; Zhou X; Huang T; Dai P; Duan D; Ma X; Yin Q; Wang X; Liu H; Chen S; Zou F; Chen X
Cell Stress Chaperones; 2016 Mar; 21(2):339-48. PubMed ID: 26786409
[TBL] [Abstract][Full Text] [Related]
30. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
31. Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway.
Qu Z; Dong H; Xu X; Feng W; Yi X
Diagn Pathol; 2013 May; 8():70. PubMed ID: 23635099
[TBL] [Abstract][Full Text] [Related]
32. Targeted polytherapy in small cell sarcoma and its association with doxorubicin.
Dumont SN; Yang D; Dumont AG; Reynoso D; Blay JY; Trent JC
Mol Oncol; 2014 Dec; 8(8):1458-68. PubMed ID: 24998445
[TBL] [Abstract][Full Text] [Related]
33. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
[TBL] [Abstract][Full Text] [Related]
34. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.
Demidenko ZN; Vivo C; Halicka HD; Li CJ; Bhalla K; Broude EV; Blagosklonny MV
Cell Death Differ; 2006 Sep; 13(9):1434-41. PubMed ID: 16311509
[TBL] [Abstract][Full Text] [Related]
37. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Pelicano H; Carew JS; McQueen TJ; Andreeff M; Plunkett W; Keating MJ; Huang P
Leukemia; 2006 Apr; 20(4):610-9. PubMed ID: 16482209
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
39. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement.
Kim HJ; Lee KY; Kim YW; Choi YJ; Lee JE; Choi CM; Baek IJ; Rho JK; Lee JC
BMC Cancer; 2015 Jul; 15():553. PubMed ID: 26219569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
